Neoadjuvant chemotherapy
Neoadjuvant chemotherapy is systemic cytotoxic treatment administered before definitive local Therapy, usually surgery and, in selected diseases, radiation therapy.
Neoadjuvant chemotherapy is systemic cytotoxic treatment administered before definitive local Therapy, usually surgery and, in selected diseases, radiation therapy. It is used to treat clinically occult micrometastatic disease early, reduce primary-tumor burden, improve the feasibility or extent of surgery, and provide an in vivo assessment of treatment response. The approach is used in several malignancies, including breast cancer—particularly some cases of triple-negative breast cancer—and selected sarcomas and other solid Tumors.
Its biological effects depend on the drug regimen and tumor characteristics. Cytotoxic agents may damage DNA, inhibit DNA synthesis, disrupt mitosis, or trigger tumor-cell death. The response can be evaluated through radiographic tumor shrinkage, pathological response, pathological complete response, and the amount of residual disease found at surgery. In breast cancer, regimens may include agents such as paclitaxel and carboplatin, although treatment selection is disease- and patient-specific. Biomarkers including the androgen receptor (Androgen receptor (AR)), androgen receptor expression, MKI67, and immunohistochemistry may contribute to tumor characterization or treatment planning, but they do not universally determine the use of neoadjuvant chemotherapy.
Neoadjuvant chemotherapy is distinct from adjuvant chemotherapy, which is given after surgery. Depending on the malignancy, it may be combined with surgery, radiation therapy, immunotherapy, or other systemic treatments. Potential benefits include tumor downstaging and improved surgical planning; limitations include treatment-related adverse events, disease progression before surgery, and the possibility that pathological response may not fully predict long-term survival outcomes. Decisions generally incorporate tumor grade, stage, performance status, comorbidities, treatment goals, and multidisciplinary assessment.
Where the papers sit
14 papers from the last 6 months study neoadjuvant chemotherapy directly · updated from PubMed 16 Nov 2026
Study type 2 clinical trials · 8 observational · 4 human data
Themes 3 themes · 1 paradigm shift
-
Breast Cancer Treatment Response
Pathologic complete response remains the main benchmark for taxane- and carboplatin-based treatment in early breast cancer, especially triple-negative disease. Anthracycline-free regimens and treatment duration are being weighed against efficacy, toxicity, and patient-reported outcomes, including in HER2-positive disease. Body composition, phase angle, symptoms, and lifestyle interventions broaden assessment beyond tumor response. DNA methylation is being explored as a treatment-associated biomarker, but real-world outcomes remain heterogeneous.
7 papers · 50%
-
Perioperative Bladder Cancer Chemotherapy
Cisplatin-based chemotherapy remains central before cystectomy for muscle-invasive bladder cancer, with carboplatin used as an alternative for some patients. Real-world comparisons of neoadjuvant and adjuvant treatment focus on overall survival and treatment sequencing. Complete responders have low reported urethral recurrence after surgery. The evidence remains observational, leaving optimal patient selection and relapse prevention unresolved.
2 papers · 14.3%
-
Others — Rare Tumor Diagnosis and Response
Rare sarcomas and other tumors are being approached through better response prediction, diagnosis, and treatment selection. MRI radiomics is being tested against radiologist assessment for Ewing sarcoma, while circulating tumor-cell markers and multidisciplinary review address diagnostic uncertainty. Concurrent neoadjuvant chemoradiotherapy is being evaluated in high-risk soft-tissue sarcoma, and regulatory T-cell changes are reported in cervical cancer. The evidence is exploratory and too heterogeneous to establish a common treatment direction.
5 papers · 35.7%
Neoadjuvant chemotherapy intensity need not be maximized to preserve benefit
The anthracycline-containing versus anthracycline-free carboplatin-based regimens study in early-stage triple-negative breast cancer and the TRAIN-3 study of chemotherapy duration in HER2-positive early breast cancer independently challenge the assumption that more intensive or prolonged neoadjuvant chemotherapy is required. In triple-negative disease, adding anthracyclines to carboplatin–taxane therapy was not associated with a higher pathologic complete-response rate, while in HER2-positive disease, stopping treatment early after an early complete response preserved efficacy and was associated with better patient-reported functioning, less fatigue, and less neuropathy. Together, these findings shift neoadjuvant treatment from a fixed maximal-intensity course toward response-guided and potentially anthracycline-free treatment 42714613Sep 42308862Jun.
Papers
The 14 papers from the last 6 months that study neoadjuvant chemotherapy directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Breast Cancer Treatment Response (7)
- Patient-reported Symptom Resolution After Neoadjuvant Versus Adjuvant Chemotherapy for Early Breast Cancer: A Prospective Observational Cohort Study. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957270
- Multimodal lifestyle intervention during neoadjuvant chemotherapy in patients with early breast cancer as a strategy to improve treatment response: Protocol of the DIANA randomized clinical trial. PloS one · 27 Oct 2026 PMID 42945273
- Investigation of DNA methylation levels before and after treatment in breast cancer patients receiving neoadjuvant chemotherapy. Breast cancer research and treatment · 18 Oct 2026 PMID 42894051
- Perioperative Body-Composition and Phase-Angle Measures in Women Undergoing Breast Cancer Surgery After Neoadjuvant Chemotherapy or Treated Through a Surgery-First Pathway (BC-NUTRITION): Exploratory 2-Cohort Pilot Analysis. JMIR formative research · 30 Sept 2026 PMID 42813825
- Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes. Breast cancer research and treatment · 9 Sept 2026 PMID 42714613
- Neoadjuvant chemotherapy in women with triple-negative breast cancer: real world results from Western Kenya. The oncologist · 14 Aug 2026 PMID 42599194
- Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study. European journal of cancer (Oxford, England : 1990) · 17 Jun 2026 PMID 42308862
Perioperative Bladder Cancer Chemotherapy (2)
- Overall Survival After Neoadjuvant Versus Adjuvant Chemotherapy for Invasive Urothelial Carcinoma of the Bladder: A Real-world Multicenter Cohort Study. Anticancer research · 27 Oct 2026 PMID 42946419
- No urethral recurrences in complete responders after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer. Scandinavian journal of urology · 29 Sept 2026 PMID 42808213
Others — Rare Tumor Diagnosis and Response (5)
- Can radiomics outperform radiologists in predicting Ewing sarcoma response to neoadjuvant chemotherapy from longitudinal MRI? BMC cancer · 12 Nov 2026 PMID 43021171
- Slug-positive circulating tumor cells in mesenchymal malignancies: what remains to validate. Journal of cancer research and clinical oncology · 19 Aug 2026 PMID 42616124
- When rare becomes real: diagnostic challenges and use of a multidisciplinary team-based decision in primary pulmonary synovial sarcoma. BMJ case reports · 17 Aug 2026 PMID 42608070
- Neoadjuvant chemotherapy reduces regulatory T-cells in cervical cancer. European journal of cancer (Oxford, England : 1990) · 14 Aug 2026 PMID 42600508
- Feasibility and Activity of Concurrent Neoadjuvant Chemotherapy and Radiotherapy in Patients with High-risk Soft-Tissue Sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jul 2026 PMID 42531374
By study type
Clinical trials (2)
- Multimodal lifestyle intervention during neoadjuvant chemotherapy in patients with early breast cancer as a strategy to improve treatment response: Protocol of the DIANA randomized clinical trial. PloS one · 27 Oct 2026 PMID 42945273
- Feasibility and Activity of Concurrent Neoadjuvant Chemotherapy and Radiotherapy in Patients with High-risk Soft-Tissue Sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jul 2026 PMID 42531374
Observational studies and case reports (8)
- Can radiomics outperform radiologists in predicting Ewing sarcoma response to neoadjuvant chemotherapy from longitudinal MRI? BMC cancer · 12 Nov 2026 PMID 43021171
- Patient-reported Symptom Resolution After Neoadjuvant Versus Adjuvant Chemotherapy for Early Breast Cancer: A Prospective Observational Cohort Study. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957270
- Overall Survival After Neoadjuvant Versus Adjuvant Chemotherapy for Invasive Urothelial Carcinoma of the Bladder: A Real-world Multicenter Cohort Study. Anticancer research · 27 Oct 2026 PMID 42946419
- Perioperative Body-Composition and Phase-Angle Measures in Women Undergoing Breast Cancer Surgery After Neoadjuvant Chemotherapy or Treated Through a Surgery-First Pathway (BC-NUTRITION): Exploratory 2-Cohort Pilot Analysis. JMIR formative research · 30 Sept 2026 PMID 42813825
- No urethral recurrences in complete responders after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer. Scandinavian journal of urology · 29 Sept 2026 PMID 42808213
- Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes. Breast cancer research and treatment · 9 Sept 2026 PMID 42714613
- When rare becomes real: diagnostic challenges and use of a multidisciplinary team-based decision in primary pulmonary synovial sarcoma. BMJ case reports · 17 Aug 2026 PMID 42608070
- Neoadjuvant chemotherapy in women with triple-negative breast cancer: real world results from Western Kenya. The oncologist · 14 Aug 2026 PMID 42599194
Human data, design not indexed (4)
- Investigation of DNA methylation levels before and after treatment in breast cancer patients receiving neoadjuvant chemotherapy. Breast cancer research and treatment · 18 Oct 2026 PMID 42894051
- Slug-positive circulating tumor cells in mesenchymal malignancies: what remains to validate. Journal of cancer research and clinical oncology · 19 Aug 2026 PMID 42616124
- Neoadjuvant chemotherapy reduces regulatory T-cells in cervical cancer. European journal of cancer (Oxford, England : 1990) · 14 Aug 2026 PMID 42600508
- Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study. European journal of cancer (Oxford, England : 1990) · 17 Jun 2026 PMID 42308862
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-08-20. Drafted by language models from published abstracts; not medical advice.